Phase I study of hV01, a recombinant human IL-21-expressing oncolytic vaccinia virus, as monotherapy in advanced solid tumors. Initial safety and efficacy results from a first-in-human, phase 1/2 ...

Outcomes of continuing neoadjuvant-intent immunotherapy for advanced, resectable cutaneous squamous cell carcinoma post-operatively. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...